Celloram
Celloram is a preclinical-stage, private for-profit company founded in 2018 and headquartered in Cleveland, Ohio, with 11-50 employees. No products, technology, therapeutic focus, or pipeline details are disclosed in available source material.
- Company typePrivate
- Founded2018
- HeadquartersCleveland, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Celloram does
Celloram is a preclinical-stage, private for-profit company founded in 2018 and headquartered in Cleveland, Ohio, with a workforce of 11-50 employees. The "preclinical stage" designation strongly indicates a biotechnology or pharmaceutical company engaged in early-stage therapeutic, diagnostic, or platform development prior to first-in-human clinical trials. The company's legal structure, size band, and location are the only firmographic facts documented; no specific therapeutic area, modality (small molecule, biologic, cell therapy, gene therapy, diagnostic), target indication, pipeline candidates, or underlying scientific platform are disclosed in the available source material.
The company's business model, revenue mechanics, and customer base are not described in any source block. The only direct primary-source data attempt—the company website at celloram.com—displayed only a verification/loading page, yielding no substantive corporate disclosures. Consequently, there are no documented products, services, technology descriptions, pricing models, go-to-market motions, customer segments, partnerships, regulatory filings, management team profiles, funding rounds, intellectual property holdings, or strategic milestones available. The source commentary explicitly flags this as a significant data gap. From an investment due-diligence perspective, Celloram presents as a sub-scale, sub-revenue preclinical life-sciences entity with no publicly verifiable technical, commercial, or capital-markets footprint in the current source set.
Source attribution for this description rests on the firmographic block, which is the only source providing structured company facts; all other sources either repeat the same null findings or confirm the verification-page state of the website.
Celloram firmographics
Firmographics- Name
- Celloram
- Website
- https://celloram.com
- Company type
- Private
- Founded year
- 2018
- Headcount range
- 11–50 employees
- Short description
- Celloram is a preclinical-stage, private for-profit company founded in 2018 and headquartered in Cleveland, Ohio, with 11-50 employees. No products, technology, therapeutic focus, or pipeline details are disclosed in available source material.
- Ownership category
- akta.pro rank
Celloram industry classification
Industry- Product category
- Biotechnology Research
- NAICS
- Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Cellomics & High-Content Screening (HCS) Services (HLAGANAD)
Keywords
Where Celloram is headquartered
LocationHeadquarters
- HQ city
- Cleveland
- HQ country
- United States
- HQ region
- North America
Markets served
Celloram business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
Celloram product offering
Product offeringCore offering
Celloram is a preclinical-stage company, indicating it is engaged in early-stage life sciences research and development activities prior to clinical trials. Specific product candidates, therapeutic areas, or commercial offerings are not disclosed in the available source material, as the company's website displayed only a verification/loading page with no substantive content.
Differentiator
Problem solved
Functional benefit
Companies that use Celloram
Customer profileIdeal customer profiles1 record
Celloram technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Celloram competitors and assessment
Company assessmentDirect peers
- Fate Therapeutics: Clinical-stage cell-therapy company developing off-the-shelf iPSC-derived NK and T-cell candidates. Comparable to Celloram as a cell-engineering platform biotech, although Fate is significantly more advanced (multiple clinical programs) and more heavily capitalized.
- Century Therapeutics: Preclinical-to-clinical iPSC-derived cell therapy company. Direct peer in modality (engineered cell therapy) and stage profile; went public via SPAC in 2021 and is a useful benchmark for capital intensity and timeline for a Celloram-like platform.
- Caribou Biosciences: Cell therapy and genome-editing company developing allogeneic CAR-T candidates. Comparable to Celloram in combining cell therapy with a core engineering/CRISPR platform, and is at a similar early-clinical inflection point.
- Nkarta: Clinical-stage cell therapy company focused on engineered NK cells for autoimmune disease and oncology. Comparable in cell-therapy modality and platform-based approach, although materially more advanced and capitalized.
Broad incumbents
- Allogene Therapeutics: Clinical-stage allogeneic CAR-T leader and one of the largest independent cell-therapy companies. A broad incumbent in the same modality that sets the competitive ceiling and partnership benchmark for smaller preclinical cell-therapy entrants like Celloram.
- BlueRock Therapeutics: Bayer-owned cell-therapy company developing iPSC-derived cell therapies, notably for Parkinson's disease. A broad incumbent that validates the cell-therapy exit pathway (large-pharma acquisition) relevant to a preclinical cell-therapy platform such as Celloram.
- Cellectis: Clinical-stage gene- and cell-therapy company with proprietary TALEN-based genome editing used to engineer allogeneic CAR-T cells. A broad incumbent in the engineered cell-therapy space that competes for similar pharma partnerships.
Emerging players
- Crispr Therapeutics: Clinical-stage gene-editing company co-developing Casgevy (exa-cel) with Vertex. Comparable in combining a cell-therapy-adjacent editing platform with pharma partnerships, and useful as a benchmark for cell-engineering platform value creation.
- Editas Medicine: Clinical-stage CRISPR-based gene- and cell-therapy company. Comparable in the cell-engineering platform thesis, though focused on in-vivo gene editing and ex-vivo edited cell therapies for hematological indications.
- Beam Therapeutics: Clinical-stage base-editing company with a growing cell-therapy footprint. Comparable as a platform biotech that could either remain independent or become a partnership / M&A target — the same strategic options available to a preclinical cell-therapy company such as Celloram.
Market position
Strengths3 records
Weaknesses3 records
Key risks4 records
Key highlights4 records
Customer concentration
Celloram social profiles
Digital presenceCelloram financial estimates
Financial estimateRevenue estimate
Valuation estimate
Celloram leadership team
Management profileNumber of profiles
Celloram funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Celloram M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Celloram
What does Celloram do?
Celloram is a preclinical-stage company, indicating it is engaged in early-stage life sciences research and development activities prior to clinical trials. Specific product candidates, therapeutic areas, or commercial offerings are not disclosed in the available source material, as the company's website displayed only a verification/loading page with no substantive content.
Is Celloram a public or private company?
Celloram is a private company. It is classified as unknown.
When was Celloram founded?
Celloram was founded in 2018. It employs 11 to 50 people.
Where is Celloram based?
Celloram is headquartered in Cleveland, United States, in the North America region.
Who are Celloram's main competitors?
Direct peers on record are Fate Therapeutics, Century Therapeutics, Caribou Biosciences and Nkarta. Broad incumbents are Allogene Therapeutics, BlueRock Therapeutics and Cellectis. Emerging players are Crispr Therapeutics, Editas Medicine and Beam Therapeutics.
Does Celloram have an API?
No public API is recorded for Celloram.
What industry is Celloram in?
Celloram's product category is Biotechnology Research. Its primary akta.pro industry code is HLAGANAD, Cellomics & High-Content Screening (HCS) Services. Its NAICS code is 541715 and its SIC code is 8731.